JCEM:B型胰岛素抵抗伪装成卵巢滤泡膜细胞增生症

2017-06-18 MedSci MedSci原创

一名29岁的妇女对胰岛素受体(B型胰岛素抵抗)产生了一种自体抗体,导致胰岛素抵抗和高胰岛素血症。睾酮激素水平上升到成年男性的范围。促性腺激素释放激素(GnRH)衍生物的治疗导致了睾酮的正常化,尽管胰岛素抵抗持续存在。

背景:

严重的高雄激素血症引起男性化在女性中是罕见的,原因包括:先天性肾上腺增生、肾上腺或卵巢肿瘤、库欣综合征和卵巢滤泡膜细胞增生症。卵巢滤泡膜细胞增生症是一种罕见且严重的功能性卵巢雄激素过多症,通常与胰岛素抵抗(IR)有关,类似于多囊卵巢综合征(PCOS)。

极端形式的胰岛素抵抗(IR),包括脂质代谢障碍,胰岛素受体的突变,或产生胰岛素受体的自体抗体(B型胰岛素抵抗),代表了胰岛素抵抗导致卵巢滤泡膜细胞增生症的发生更急剧的例子,并且可能与大量卵巢增生和成年男性范围内的睾丸激素水平有关。

高胰岛素血症可导致病理性的卵巢生长和雄性激素的分泌。

案例描述:

一位先前健康的29岁非裔美国女性患有继发性闭经,在8个月后并发多尿症,多饮,体重减轻了20磅(9.1公斤)。血糖为40到400mg/dl;糖化血红蛋白为6.1%。她出现了男性化的症状,包括声音变低沉,乳房缩小,机器人体型,痤疮,阴蒂肥大,多毛症,以及愤怒增加。脸、腋窝、肘和腹部的皮肤变黑。

实验室评估发现,总睾酮和游离睾酮水平显着升高:[总睾酮:450~610ng/dl(正常:2~45ng/dl),游离睾酮:25.6pg/ml(正常:0.2~5pg/ml)。肾上腺雄激素正常[17-羟孕酮:102ng/dl(正常:<185ng/dl),脱氢表雄酮硫酸盐:84μg/dL(正常:40~325 μg/dL)]。促性腺激素是正常:促黄体激素(LH):13.7IU/ml,促卵泡激素:5.1IU/ml。胰岛素样生长因子1为100 ng/dl(正常:117~329 ng/dl)。轻度全血细胞减少症显着。成像显示,双侧卵巢增大,大量的卵泡与多囊性卵巢综合症(PCOS)相一致,未见肿块;肾上腺正常。尽管有这些成像结果,但由于睾丸激素升高的严重程度,仍怀疑为卵巢肿瘤。因此,进行了卵巢静脉取样,结果显示双侧睾酮水平>1500mg/dl。

该患者接受了卵巢滤泡膜细胞增生症的推定诊断,并肌内注射22.5mg醋酸亮丙瑞林。给予醋酸亮丙瑞林三个月后,病人接受了知情同意后,由国家糖尿病消化和肾脏疾病研究所的机构审查委员会批准,在美国国立卫生研究院进行了病史研究。

患者的情绪和肤色有所改善;除了偶尔的空腹低血糖之外,血糖正常;体重增加;阴蒂肥大消退。检查结果显示,颈部和颧骨分布有多毛症和轻度黑棘皮病。睾丸激素低于20ng/dl,LH是0.4 U/L,促卵泡激素是2.1 U/L,空腹胰岛素是29.3 μU/mL。存在胰岛素受体的血清抗体,诊断为B型胰岛素抵抗。

一名29岁的妇女对胰岛素受体(B型胰岛素抵抗)产生了一种自体抗体,导致胰岛素抵抗和高胰岛素血症。睾酮激素水平上升到成年男性的范围。促性腺激素释放激素(GnRH)衍生物的治疗导致了睾酮的正常化,尽管胰岛素抵抗持续存在。

结论:

这一案例表明,胰岛素会引起病理卵巢雄激素的分泌,而且促性腺激素是一个必需因素。对患有高胰岛素血症并发严重的雄激素过多症或卵巢增大症的患者来说,用促性腺激素释放激素(GnRH)衍生物来抑制促性腺激素,可能是一种有用的治疗方法。

原始出处
Rebecca J. Brown, Jalaja Joseph, Elaine Cochran, et al. Type B Insulin Resistance Masquerading as Ovarian Hyperthecosis. JCEM. 2017 June. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048335, encodeId=c1a2204833523, content=<a href='/topic/show?id=55d2382125' target=_blank style='color:#2F92EE;'>#B型胰岛素抵抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3821, encryptionId=55d2382125, topicName=B型胰岛素抵抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Fri Dec 01 07:37:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777604, encodeId=ac261e77604c5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Mar 12 18:37:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062986, encodeId=752f2062986de, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Oct 03 16:37:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749745, encodeId=de611e497459b, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sat Jul 29 20:37:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048335, encodeId=c1a2204833523, content=<a href='/topic/show?id=55d2382125' target=_blank style='color:#2F92EE;'>#B型胰岛素抵抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3821, encryptionId=55d2382125, topicName=B型胰岛素抵抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Fri Dec 01 07:37:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777604, encodeId=ac261e77604c5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Mar 12 18:37:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062986, encodeId=752f2062986de, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Oct 03 16:37:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749745, encodeId=de611e497459b, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sat Jul 29 20:37:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
    2018-03-12 smallant2015
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048335, encodeId=c1a2204833523, content=<a href='/topic/show?id=55d2382125' target=_blank style='color:#2F92EE;'>#B型胰岛素抵抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3821, encryptionId=55d2382125, topicName=B型胰岛素抵抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Fri Dec 01 07:37:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777604, encodeId=ac261e77604c5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Mar 12 18:37:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062986, encodeId=752f2062986de, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Oct 03 16:37:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749745, encodeId=de611e497459b, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sat Jul 29 20:37:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
    2017-10-03 achengzhao
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048335, encodeId=c1a2204833523, content=<a href='/topic/show?id=55d2382125' target=_blank style='color:#2F92EE;'>#B型胰岛素抵抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3821, encryptionId=55d2382125, topicName=B型胰岛素抵抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Fri Dec 01 07:37:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777604, encodeId=ac261e77604c5, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Mar 12 18:37:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062986, encodeId=752f2062986de, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Oct 03 16:37:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749745, encodeId=de611e497459b, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sat Jul 29 20:37:00 CST 2017, time=2017-07-29, status=1, ipAttribution=)]
    2017-07-29 baoya

相关资讯

Diabetes:健康人急性低血糖损害骨骼肌中胰岛素刺激的葡萄糖摄取和糖原合酶!

胰岛素刺激的骨骼肌葡萄糖处理和葡萄糖清除受损,而对葡萄糖转运的胰岛素信号不受低血糖的影响。在高胰岛素低血糖期间,胰岛素刺激糖原合成酶的活性可以被完全抵消,并且通过PKA和磷酸化的儿茶酚胺的信号通路可以抑制糖原合成酶的位点均有所增加。

N Engl J Med:2型糖尿病患者中,谷德胰岛素和甘精胰岛素的有效性和安全性对比

谷德胰岛素是一种被批准用于成人,青少年和儿童糖尿病的超长效胰岛素类似物,每日一次基础胰岛素注射可持久、平稳的降低血糖。以前的开放研究显示,相比甘精胰岛素,谷德胰岛素降糖效果的每日变异率和低血糖风险均较低。然而,在心血管安全性方面,尚缺乏谷德胰岛素的研究报告。

JCEM:作用于胰岛素受体的人单克隆抗体——X358,安全性和耐受性良好

在糖尿病治疗方面,胰岛素分泌功能受损的患者需要一种新颖的改良的治疗模式。传统的单克隆抗体在配体 - 受体结合位点结合,以提供完全活化或类似开关的抑制。然而,受体也有很多位点,称为变构位点,它就像调节开关一样调节配体 - 受体之间相互作用。目前的研究已经发现了胰岛受体三种不同类别的变构抗体,并且他们发挥不同的作用。X358是一个作用于胰岛素受体(INSR)的人源性单克隆抗体,是胰岛素信号转导时的负别

ADA 2017:DEVOTE研究证实德谷胰岛素具有心血管安全性且严重低血糖大幅减少

6月12日,心血管安全性终点研究DEVOTE在ADA2017重磅公布,该研究首次头对头比较了两种基础胰岛素——德谷胰岛素和甘精胰岛素U100在2型糖尿病患者中的心血管安全性。结果证实,新型超长效胰岛素制剂德谷胰岛素的心血管安全性与甘精胰岛素U100相当,但较甘精胰岛素U100显着降低了40%的严重低血糖,夜间严重低血糖显着降低53%。

CLIN PHARMACOKINET:1型糖尿病患者速效型胰岛素的药代动力学和药效学特征

速效胰岛素(速效天冬胰岛素)是一种新胰岛素门冬胰岛素(IAsp)制剂,它能够模拟内源性胰岛素快速释放。在六项临床药理学试验的汇总数据的事后分析中,研究人员比较了速效天冬胰岛素和IAsp的药理学特征。

SCI ADV:新胰岛移植术有望使糖尿病患者彻底摆脱外源胰岛素治疗!

【新的移植技术使1型糖尿病患者获益】将新的水凝胶材料与促进血管生长的蛋白质结合可以提高将生产胰岛素的胰岛细胞移植到1型糖尿病患者体内的成功率。在动物模型中,该技术提高了移植胰岛素生产细胞的存活率,恢复胰岛素产生以响应于血糖水平和治愈这些糖尿病动物。